Gamida Cell’s $75 Million Shares Offering

Davis Polk advised the representatives of the underwriters in the offering.

Gamida Cell Ltd completed the $75 million SEC-registered follow-on offering of 9,343,750 ordinary shares, which includes 1,218,750 ordinary shares from the full exercise of the underwriters’ over-allotment option to purchase additional ordinary shares. The ordinary shares are listed on the Nasdaq Global Market under the symbol “GMDA.”

Based in Jerusalem, Israel, Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.

The Davis Polk corporate team advising Piper Sandler & Co. and Evercore Group L.L.C., as representatives of the several underwriters, included partner Derek Dostal (Picture) and associates Gil Savir and Yushen Liu. The intellectual property and technology transactions team included partner David R. Bauer and associate Jesse L. Hallock. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Derek Dostal – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Yushen Liu – Davis Polk & Wardwell; Gil Savir – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Evercore Inc.; Piper Sandler;


Author: Ambrogio Visconti